Business
UroGen Pharma Expands Executive Team to Accelerate Platform Innovation and Drive Commercial Growth
Diversity of Experience Brings New Insight and Proven Leadership to Support Advanced Commercial Structure While Balancing Continuity in Key Positions Molly
About this update from Urogen Pharma Ltd.
[{"type":"text","content":"\n\nDiversity of Experience Brings New Insight and Proven Leadership to Support Advanced Commercial Structure While Balancing Continuity in Key Positions\n\n\nMolly Henderson Named Chief Financial Officer\n\n\nJason Smith Named General Counsel and Chief Compliance Officer\n\n\nPolly A. Murphy, DVM, Ph.D., Named Chief Business Officer\n\n\n\n\n PRINCETON, N.J.--(BUSINESS WIRE)--\nUroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the appointment of three new executives to the Company's Executive Leadership Team (ELT). These new hires, all of whom will report to Liz Barrett, President and Chief Executive Officer of UroGen, bring a breadth of experience to help execute the Company's business objectives in the near-term and its growth strategies for the long-term in support of pipeline development, RTGel™ platform expansion, access to external innovation and financial performance.\n\n\n“I am excited to welcome these highly-skilled executives, two of whom I've worked with in the past, and am confident that they will bring tremendous energy, diversity and experience to UroGen as we develop transformative medicines for patients,” said Ms. Barrett. “The refashioning of the ELT, a process that began when I first joined the company, is now complete and I am pleased to have the partnership of a strong leadership team to support an advanced commercial structure and drive pipeline innovation as we seize the opportunity to fundamentally change the way urologic cancers are treated.”\n\n\nMolly Henderson has been named Chief Financial Officer. Ms. Henderson will join UroGen on October 1, 2020, from Advaxis, a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products where she served as Executive Vice President and Chief Financial Officer. Ms. Henderson is also on the Board of Directors and Chair of the Audit Committee of Calliditas. Prior to these roles, she was Chief Financial Officer at Iovance Biotherapeutics, Inc. (formerly Lion Biotechnologies, Inc.), an immuno-oncology company where she was responsible for all financial, Securities and Exchange Commission reporting, legal, governance, human resources and IT-related functions, including raising $100 m...